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A B S T R A C T
The present work investigates in vitro the delivery of the anticancer drug mitoxantrone (MTX) to HeLa
cancer cells by means of polyethylene glycol (PEG) liposomes functionalized with the novel cell
penetrating peptide gH625. This hydrophobic peptide enhances the delivery of doxorubicin (Doxo) to the
cytoplasm of cancer cells, while the mechanism of this enhancement has not yet been understood. Here,
in order to get a better insight into the role of gH625 on the mechanism of liposome-mediated drug
delivery, we treated HeLa cells with liposomes functionalized with gH625 and loaded with MTX;
functionalized and not liposome were characterized in terms of their physico-chemical properties and
drug release kinetics. To quantify the MTX uptake and to study the subcellular drug distribution and
interaction, we took advantage of the intrinsic ﬂuorescence of MTX and of the ﬂuorescence-based
techniques like ﬂuorescence-activated cell sorting (FACS) and confocal spectral imaging (CSI). FACS data
conﬁrmed that gH625 increases the total intracellular MTX content. CSI data indicated that when
liposomes are decorated with gH625 an enhanced staining of the internalized drug is observed mainly in
hydrophobic regions of the cytoplasm, where the increased presence of an oxidative metabolite of the
drug is observed. The cytotoxicity on HeLa cell line was higher for functionalized liposomes within 4–6 h
of treatment. To summarise, the MTX delivery with gH625-decorated nanoliposomes enhances the
quantity of both the intracellular drug and of its oxidative metabolite and contributes to higher
anticancer efﬁcacy of the drug at the delay of 4–6 h.
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Cancer remains a leading cause of death in the western world.
Cancer chemotherapies usually involve the use of cytotoxic
molecules which kill highly proliferative cancer cells but also
other proliferative cells in bone marrow, the gastrointestinal tract
and hair follicles leading to common side effects such as
compromised immune system, hair loss etc. (Dawidczyk et al.,* Corresponding author. Tel.: +33 247367162.
** Corresponding author. Tel.: +39 812536642.
E-mail addresses: sgaldier@unina.it (S. Galdiero), igor.chourpa@univ-tours.fr
(I. Chourpa).
http://dx.doi.org/10.1016/j.ijpharm.2015.04.039
0378-5173/ã 2015 Elsevier B.V. All rights reserved.2014). Mitoxantrone (MTX) is a synthetic anthracenedione
antineoplastic agent derived from the anthraquinone dye ametan-
trone (Dunn and Goa, 1996). It is structurally similar to the
anthracycline agent doxorubicin (Doxo), both drugs having a
planar aromatic ring structure which enables them to interact with
DNA by intercalation between base pairs. MTX can inhibit the
activity of nuclear enzyme DNA topoisomerase (II), interfere with
RNA and cause the crosslink of DNA and strand breaks and produce
reactive oxygen species. MTX is believed to lack cell cycle phase
speciﬁcity because it has cytocidal effects both on proliferating and
non-proliferating cells (Wiseman and Spencer, 1997). Similar to
Doxo, its main side effect is cardiotoxicity; although also
neutropenia, bone marrow suppression and secondary acute
myelogenous leukaemia have been reported in patients treated
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produce free radicals to a much lesser degree than Doxo (Novak
and Kharasch, 1985).
Actual treatments of cancer disease remains an elusive
alternative, offering limited efﬁcacy with extensive secondary
effects as a result of severe cytotoxic effects in healthy tissues. The
advent of nanotechnology brought the promise to revolutionize
many ﬁelds including oncology, proposing advanced systems for
cancer treatment. Drug delivery systems are amongst the most
successful examples of nanotechnology and allow the reduction of
unwanted side effects of systemic delivery, while increasing drug
accumulation in tumours and improving the therapeutic efﬁcacy.
A delivery tool should transport the drug to the target cells not only
with high efﬁcacy, but also with minimal toxicity and immune
response avoiding its degradation and entrapment in endosomes.
The development of a broad range of nanoparticle platforms with
the ability to tune size, composition and functionalities has
provided a signiﬁcant resource for nanomedicine.
Liposomes play a key role as drug carriers and represent a
relatively simple form of nanovectors, especially for the delivery of
antineoplastic drugs (Cui et al., 2008; Madni et al., 2014); in fact,
they modify the pharmacokinetics and biodistribution of the drug,
thus resulting in lower toxicity and higher efﬁcacy. Liposomes are
able to selectively deliver the drug into malignant areas due to
enhanced permeability and retention effects (EPR). As a result, the
exposure of healthy tissues to toxic drugs is reduced and
therapeutic indexes are improved. Unfortunately, following
intravenous injection, many nanoliposomes are easily recognised
by the reticulo endothelial system (RES) resulting in rapid
clearance and nonlinear pharmacokinetics. To reduce this effect,
polyethylene glycol (PEG) has been introduced on the surface of
liposomes. This modiﬁcation is a milestone breakthrough in the
ﬁeld of drug delivery and is widely known as stealth technology.
PEG-coated liposomes display a good pharmacokinetic proﬁle and
reduced systemic toxicity; however, their uptake in cells is delayed.
In order to facilitate the interaction between liposomes and cells,
the liposome surface can be functionalized with cell penetrating
peptides (CPPs). CPPs have received much attention because of
their ability to enable several kinds of cargoes to cross cell
membranes both in vitro and in vivo (Heitz et al., 2009; Galdiero
et al., 2014). CPPs are short and usually basic amino acid rich
peptides originating from proteins like the viral TAT protein that
are able to cross biological barriers. The CPPs uptake mechanism is
highly debated and is thought to involve mainly the endocytic
pathway. Trapping the conjugated cargo in endosomes, eventually
landing in lysosomes where common enzymatic degradation
mechanisms take place, often leads to a limited delivery of
therapeutic agents to targets (Choi and David, 2014).
Hydrophobic peptides, that efﬁciently traverse biological
membranes, promote lipid–membrane reorganizing processes
and involve temporary membrane destabilization (Galdiero
et al., 2014, 2015, 2012; Falanga et al., 2009), are able to avoid
endosomal entrapment either favouring the escape from the
endosome or by translocating directly into the cytosol, thus
favouring energy independent processes. This idea has been
exploited to design the drug delivery tool called gH625 (Galdiero
et al., 2015; Valiante et al., 2015), which can be efﬁciently linked to
different potential therapeutic molecules and/or nanovectors and
represents an extremely powerful tool to increase their uptake.
gH625 is a peptide derived from glycoprotein H of Herpes simplex
virus type I, which has been shown to have many applications,
from membrane fusion (Galdiero et al., 2005), to viral inhibition
(Galdiero et al., 2008; Tarallo et al., 2013) and drug delivery
(Galdiero et al., 2012). gH625 has the ability to penetrate deep into
the bilayer as a helix without causing signiﬁcant bilayer
perturbations. This ability may help explaining its translocationacross the bilayer. It has been recently demonstrated that gH625 is
able to transport into the cytosol several compounds, such as
quantum dots (QDs) (Falanga et al., 2011), liposomes (Tarallo et al.,
2011), nanoparticles (NPs) (Guarnieri et al., 2013), dendrimers
(Carberry et al., 2012; Falanga et al., 2014), and proteins (Smaldone
et al., 2013).
The cellular uptake of liposomes or other nanosystems
decorated on their surface with gH625 has been previously
determined by ﬂow cytometry (Fluorescence-activated cell sorting
– FACS) and confocal ﬂuorescence microscopy (Falanga et al., 2011;
Tarallo et al., 2011). It has been shown that the mechanism of
nanosystem uptake could be modiﬁed by the presence of the
peptide and that the internalization of functionalized nanosystems
is mainly not energy-dependant. However, the analysis was limited
to the overall detection of the drug used and did not account for the
subcellular ﬂuorescence changes, depending on the drug environ-
ment/interaction. Confocal spectral imaging (CSI) represents an
alternative technique based on measurement, at different points of
a cell, of the ﬂuorescence spectra, which provides the opportunity
to distinguish different molecular states of the intracellular drug
(Sharonov et al., 1994). Thus, CSI is a powerful tool for mapping the
MTX molecular interactions within compartments of living cells.
In this work, in order to get a better insight into the role of
gH625 on the mechanism of liposome-mediated drug delivery, we
have performed a comparative study of HeLa cells treated with
MTX-loaded PEGylated liposomes (LMTX) and from LMTX
functionalized with gH625 (LMTX-gH625). Prior to cellular
experiments, the liposomes were carefully characterized in terms
of their physical properties (hydrodynamic size, surface charge),
chemical composition (MTX content, gH625 conformation) and
drug release kinetics. Both the FACS data on the quantity of total
intracellular MTX, the CSI data on the subcellular drug distribu-
tion/interaction and the cytotoxicity assay data indicate that the
functionalization of liposomes with the peptide gH625 affects the
drug delivery qualitatively and quantitatively.
2. Material and methods
2.1. Materials
Fmoc-protected amino acid derivatives, coupling reagents, and
Rink amide p-methylbenzhydrylamine (MBHA) resin were pur-
chased from Calbiochem-Novabiochem (Laufelﬁngen,
Switzerland). Fmoc-L-propargylglycine (Fmoc-Pra-OH) was pur-
chased from Polypetide (Strasbourg, France). Mitoxantrone and
other chemicals were purchased from Sigma–Aldrich, Fluka
(Buchs, Switzerland), or LabScan (Stillorgan, Ireland) and were
used as received, unless otherwise stated. 1,2-Dioleoyl-sn-glycero-
3-phosphocholine (DOPG) and 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[amino(polyethylene glycol)-2000] (ammo-
nium salt) were purchased from Avanti Polar Lipids (Alabaster, AL).
HeLa, cervical cancer cell of an African–American woman was
purchased from ATCC, Rockille, (MD, USA), Dulbecco’s Minimal
Essential Medium was obtained from Gibco, Invitrogen Co.
(Carlsbad, CA, USA), foetal bovine serum was obtained from
Euroclone, Milan, Italy, 100 mg/ml sodium pyruvate, 100 g/ml of
nonessential aminoacids, 100 g/ml penicillin/streptomycin and
100 U/ml glutamine was bought from Invitrogen Life Technologies,
Italy and Hank’s Balanced Salt Solution from Fisher Bioblock
Scientiﬁc, Illkirch, France. Other reagents were all of analytical
grade.
2.2. Solid-phase peptide synthesis
gH625 was synthesized using standard solid-phase 9-ﬂuore-
nylmethoxycarbonyl (Fmoc) procedures with a Syro I
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as previously reported (Galdiero et al., 2005).
The Rink amide MBHA resin (substitution 0.51 mmol/g) was
used as the solid-phase support, and syntheses were performed on
a scale of 20 mmol. The peptide was synthesized by consecutive
deprotecting and coupling step. Coupling: Fmoc-protected amino
acids (4 equivalents relative to resin loading) HBTU (0.5 M in DMF,
4 equiv), HOBt (0.5 M in DMF, 4 equiv), and DIPEA (2 M in DMF, 8
equiv). Deprotection: 30% piperidine in DMF (v/v).
The gH625-Pra was synthesized to allow binding to preformed-
liposomes. Fmoc-Pra-OH was coupled once for 45 min with
2 equivalents of PyBop/HOBt and 4 equivalents of DIPEA. The
peptide was fully deprotected and cleaved from the resin with a
solution of TFA/water/anisole/thioanisole 93.5/2.5/2.0/2.0, at room
temperature for 300 min. Then, it was precipitated with ice-cold
ethyl ether, ﬁltered, dissolved in water, and lyophilized. Puriﬁca-
tion was performed by RP-HPLC on a LC8 Shimadzu HPLC system
(Shimadzu Corporation, Kyoto, Japan) equipped with a UV lambda-
Max Model 481 detector using a Phenomenex (Torrance, CA) C18
(300 Å, 250  21.20 mm, 5 m) column eluted with H2O/0.1% TFA (A)
and CH3CN/0.1% TFA (B) from 20 to 80% over 20 min at a ﬂow rate of
20 ml/min. Purity and identity were assessed by analytical LC–MS
analyses using a Finnigan Surveyor MSQ single quadrupole
electrospray ionization (Finnigan/Thermo Electron Corporation,
San Jose, CA), column: C18-phenomenex eluted with H2O/0.1% TFA
(A) and CH3CN/0.1% TFA (B) from 20 to 80% over 10 min at a ﬂow
rate of 0.8 ml/min. The ﬁnal yield of puriﬁed peptide ranged
between 30 and 40%. Azide-AdOO-Lys(C(O)CH2CH2C(O)N-
(C18H37)2)-amide ((C18)2L-N3) monomer was synthesized on solid
phase under standard conditions using the Fmoc/tBu strategy as
previously reported (Tarallo et al., 2011).
2.3. Liposomes preparation
Liposomes were prepared by the thin lipid ﬁlm hydration
procedure. Mixed aggregates of DOPG/DSPE-PEG/(C18)2L-N3
(85:5:10 molar ratio) were prepared by dissolving the lipids in a
small amount of chloroform, and subsequently evaporating the
solvent by slowly rotating the tube containing the solution under a
stream of nitrogen and eventually lyophilized overnight. A thin
ﬁlm of amphiphiles was obtained. The dry lipid ﬁlm was
suspended in HEPES–NaCl buffer (5 mM–100 mM) at pH 7.4 by
vortexing; then the lipid suspension was freeze–thawed ten times
and extruded ten times thought a polycarbonate membrane with
100 nm pore size using a thermobarrel extruder (Northern Lipids
Inc., Canada).
2.4. Functionalization of liposomes with gH625
The click reaction was carried out on DOPG/DSPE-PEG/(C18)2L-
N3 liposomes adding CuSO45H2O (4.4 equiv), ascorbic acid (6.7
equiv), and the peptide derivative (1 equiv) with respect to the
azido moiety. In particular, solutions containing CuSO45H2O
(60.5 mM, solution A), ascorbic acid (81.4 mM, solution B), and
the alkyn-modiﬁed peptide (1 mM, solution C) were freshly
prepared in water.
Solution A (11.6 ml), solution B (13.2 ml), and solution C (145.4 ml)
were added to a suspension of azido-functionalized preformed
liposomes in HEPES–NaCl buffer (400 ml). The concentration of
solution C was determined measuring the tryptophan absorbance at
280 nm on a UV/vis Jasco V-5505 spectrophotometer.
The reaction mixture was stirred at 40 C for 30 min and then
left overnight at room temperature. After the conjugation step the
liposomes were puriﬁed by exclusion chromatography on a
1 18 cm Sephadex G-50 (Amersham Biosciences) column
pre-equilibrated with HEPES buffer.2.5. MTX encapsulation in liposomes
MTX was remote-loaded in DOPG/DSPE-PEG/(C18)2L-N3 lipo-
somes through an ammonium sulphate gradient method. Brieﬂy, a
liposomal solution was prepared as reported above in an
ammonium sulphate solution (250 mM) at pH 5.5. Next, the
external buffer was removed by ultra centrifugation at 151,332  g,
at 4 C for 3 h, and the liposomes were resuspended in 400 ml of
HEPES–NaCl buffer (5 mM–100 mM) at pH 7.4. A MTX solution
(18 ml at 2 mg/ml) in water was added to the liposomal solution, to
achieve a ﬁnal lipid to drug weight ratio of 10:1. This suspension
was stirred for 30 min at 60 C. Unloaded MTX was removed with a
Sephadex G50 column for determination of entrapment efﬁciency.
The MTX concentration was determined by UV spectroscopy
measuring the drug absorbance at l = 655 nm. The Drug Loading
Content (DLC, deﬁned as the weight ratio of encapsulated drug vs
the amphiphilic moieties) was quantiﬁed by subtracting the
amount of MTX removed from the total amount loaded. Finally, the
MTX pre-loaded liposomes were modiﬁed with gH625 by using the
click-chemistry reaction procedure, as reported above.
2.6. Quantiﬁcation of MTX loaded into the liposomes
The presence of copper in Lipo-MTX-gH625 determines the
formation of a complex between copper and MTX which quenches
ﬂuorescence and absorbance of the drug. In order to verify that the
quantity of MTX in both liposomes conjugated or not with the
peptide were equal, both preparations were treated with 0.2%
Triton X-100 and then with EDTA (10 mM, 91 ml) with incubation
for 1 h at 37 C. Finally, the drug absorbance measured at 655 nm
was used to determine its concentration according to the
previously established calibration curve.
2.7. Particle size and zeta potential analyses
The hydrodynamic diameter (DH) and the polydispersity index
(PDI) of LMTX and LMTX-gH625 were measured using dynamic
light scattering (DLS) method (Malvern Nanosizer Nano ZS,
Malven, UK). The zeta potential was determined using Malvern
Nanosizer NanoZS (Malvern, Malven, UK). The instrument use a
He–Ne laser 4 mW source operating at 633 nm with the scattering
angle ﬁxed at 173. Each measurement was performed at 25 C, at
least in triplicate.
2.8. gH625 conformation monitoring by circular dichroism (CD)
CD spectra in the range from 260 to 195 nm were recorded with
a Jasco J-810 spectropolarimeter equipped with a NesLab RTE111
thermal controller unit. For the measurements, liposomes
decorated with gH625 were diluted 10 times in a H2O and placed
in a 10 mm quartz cellstabilized at 25 C. Other experimental
settings were: scan speed of 10 nm min1, sensitivity of 50 m deg,
time constant of 16 s, bandwidth of 1 nm. Each spectrum was
obtained through averaging three scans, subtracting the contri-
butions from other species present in solution, and converting the
signal to mean molar ellipticity.
2.9. In vitro drug release
The in vitro release kinetics of MTX from liposomes was
determined using UV–vis spectrophotometry. LMTX and LMTX-
gH625 at equivalent MTX concentration were placed into 2 ml of
HEPES–NaCl buffer and into under continuous stirring at 37 C. The
release studies were carried out in triplicate. At predetermined
time intervals, 200 ml aliquots were withdrawn and replaced with
equal volume of fresh medium. The free drug was collected by a
Fig. 1. Circular dichroism spectrum of gH625 conjugated to blank liposomes and of
gH625 alone.
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vis absorbance at 655 nm using a previously established calibration
curve. The cumulative amount of MTX released over 24 h was
quantiﬁed, and results were plotted against incubation time.
2.10. In vitro cytotoxicity studies
The estimation of cell viability was performed by staining with
Trypan Blue (TB) (Invitrogen). This marker, added to a cell
suspension, is able to cross cell membranes that have been
changed signiﬁcantly. The TB penetrates only into damaged cells
giving them a blue colour observable under anoptical microscope.
The viable cells, which are not permeable to the marker, remain
colourless. This assay was performed on HeLa, cervical cancer cell
of an African–American woman (ATCC, Rockille, MD, USA, CCL-2)
grown as monolayers in Dulbecco’s Minimal Essential Medium
(Gibco BRL, Invitrogen Corporation, Carlsbad, CA, USA), supple-
mented with 10% foetal bovine serum (FBS – Euroclone, Milan,
Italy), 100 mg/ml sodium pyruvate, 100 g/ml of nonessential
aminoacids, 100 g/ml penicillin/streptomycin and 100 U/ml gluta-
mine (Invitrogen – Life technologies, Italy). These cells were
cultured at 37 C, in a humidiﬁed incubator in presence of 5% CO2,
using sterile ﬂasks. After reaching the conﬂuence of the ﬂask, the
medium was removed and the cells were washed with phosphate
buffer saline (PBS). Subsequently, the cells were incubated with a
solution of trypsin (0.05% trypsin, 0.0022% EDTA) and PBS at 37 C
in the presence of 5% CO2 for 3 min. Finally, the cells detached from
the ﬂask were transferred into a sterile tube (Falcon) and
centrifuged at 325  g for 10 min. The cell pellet obtained was
resuspended in fresh culture medium and the cells were seeded in
12 well plates (Falcon) in complete medium at a concentration of
350.000–400.000 cells/well. The following day, the cells were
treated with different concentrations of LMTX and LMTX-gH625;
controls were used as untreated cells (negative control) and cells
treated with H2O2 (positive control). At the end of the treatments
of 1, 4, 6,12, 24, 48 and 72 h, the cells were washed three times with
PBS to remove the liposomes in excess, and then trypsinized. The
cells completely detached were transferred in falcon tubes and
25 ml of the cell suspension were mixed with 475 ml of TB. The cells
were counted using the appliance Countess1 Cell Counter
(Invitrogen). The results were expressed as percentage of control.
2.11. In vitro cellular uptake by ﬂow cytometry
The cellular uptake of MTX-loaded liposomes was analysed by
ﬂow cytometry. HeLa cells, cultured in Dulbecco’s Minimal
Essential Medium supplemented with 10% foetal bovine serum,
were seeded into six-well at a density of 3  105 cells/ml at 37 C for
48 h. Then, cells were treated with a ﬁnal concentration of 5 mM of
LMTX and LMTX-gH625 in PBS medium for 1 and 4 h in a volume of
1 ml. Thereafter, cells were washed three time, trypsinized,
harvested and then resuspended in 0.5 ml of PBS. The MTX
ﬂuorescence associated to the cells was measured by FACs analysis
(BD Accuri), using FL4 channel 675/25 nm. The events collected
were ten thousand and BD Accuri C6 software was used to calculate
mean ﬂuorescence intensity (MFIs) for each sample. MFIs values
were reported as histogram.
2.12. In vitro cellular uptake and distribution by confocal spectral
imaging (CSI)
HeLa cells were plated at a density of 4 104 cells/well in
24-well plates onto cover glasses for 48 h in DMEM media
supplemented with 10% serum. HeLa cells were then incubated
with either LMTX or LMTX-gH625 at drug concentration of 1 mM
for 1 and 4 h at 37 C in DMEM media without serum. After theincubation with the liposomes, the medium was removed and the
cells were washed three times with fresh HBSS (Hank's Balanced
Salt Solution, Fisher Bioblock Scientiﬁc, Illkirch, France). Washed
cells were placed between slide and slip cover. Fluorescence
measurements were carried out using a LabRAM confocal micro-
spectrometer (Horiba, Villeneuve d’Ascq, France). The MTX
ﬂuorescence was excited with a 632.8 nm line of an internal,
air-cooled, helium–neon laser. The power on the samples was
30 mW, the acquisition time was 0.02 or 0.05 s/spectrum. After
the acquisition, all the spectra were normalized to an intensity
corresponding to the same acquisition duration. Treatment of
spectral maps was made using LabSpec 4.18 software (Horiba
Villeneuve d’Ascq, France).
3. Results
3.1. Physico-chemical properties of liposomes
3.1.1. Synthetic components
The liposome component (C18)2L-N3 and the peptide gH625
bearing a propargylglycine moiety (gH625-Pra) were synthesized
by the standard solid phase peptide synthesis (SPPS) protocols
with Fmoc/tBu (tBu = tert-butyl) chemistry. The alkyne moiety was
introduced at the C-terminus of the peptide as an L-propargylgly-
cine. The compounds identity and the purity were conﬁrmed by
mass spectrometry, 1H and 13C NMR spectroscopy (for (C18)2L-N3),
and LC–MS (Tarallo et al., 2011). Both gH625-Pra and (C18)2L-N3
were collected in good yields (30–40% and 85%, respectively) after
HPLC-RP puriﬁcation.
3.1.2. Blank liposomes
Liposomes coated with PEG (DOPG/DSPE-PEG/(C18)2L-N3lipo-
somes) were generated according to classical procedures (Hope
et al., 1985). Brieﬂy, the lipid mixture was dissolved into
ammonium sulphate buffer and then the suspension was extruded
ten times through a polycarbonate membrane (100 nm).
3.1.3. MTX-loaded liposomes
To obtain the MTX-loaded liposomes (LMTX) we used the
well-assessed procedures based on an ammonium sulphate
gradient (Tardi et al., 1996); in particular, a solution containing
MTX was incubated with liposomes under stirring for 30 min
at 60 C. Subsequently, unloaded MTX was removed using a
Sephadex G50 column pre-equilibrated with HEPES–NaCl buffer
(5 mM–100 mM) at pH 7.4. The drug/lipid weight ratio chosen
Table 1
Colloidal characteristics of LMTX and LMTX-gH625.
Liposome type Hydrodynamic diameter, nm Polydispersity index Zeta potential, mV
LMTX 111.80  1.42 0.09  1.01 26.30  1.01
LMTX-gH625 122.00  1.05 0.19  0.07 21.30  1.10
Data obtained for three independently prepared batches of each liposome type, with atlease 13 runs per batch.
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as it or were modiﬁed with the gH625-Pra peptide (to become
LMTX-gH625) via click-chemistry reaction performed in aqueous
medium. The coupling of the Pra moiety of the gH625 to the
liposomes surface was obtained due to a copper(I)-catalyzed
Huisgen 1,3-dipolar cycloaddition reaction of azides and alkynes
(Said Hassane et al., 2006). Cu(I) catalyser was generated in situ by
reduction of CuSO4 with ascorbic acid (Sharma and Sharma, 1997).
The LMTX-gH625 were obtained with a yield higher than 90% after
12 h at room temperature. Circular dichroism (CD) spectra showed
that gH625 when conjugated to liposomes at a concentration of
1.25 106M adopts an a helical conformation (Fig. 1), while the
peptide alone in buffer adopts a random coil structure; suggesting
that the coupling on the surface of the liposomes was sufﬁcient to
induce the secondary structure which is probably playing a key
role in translocation across the membrane bilayer.
Dynamic light scattering (DLS) data on LMTX and on
LMTX-gH625 dispersed in aqueous medium at pH 7 (Table 1)
showed that the liposome functionalization with gH625 only
slightly increased their average hydrodynamic diameter, from ca.
112 to 122 nm. The polydispersity index changed from ca. 0.09 to
ca. 0.19, indicating that the distribution of the liposome size
remained rather narrow and there are no signs of aggregation.
These parameters should favour both the effective extravasation of
liposomes and their longer retention in tumour tissues.
The surface charge of the liposomes, as determined by
measurement of their zeta potential, was also slightly reduced
on going from LMTX to LMTX-gH625, from ca. 26 to 21 mV
(Table 1). It is widely accepted that at high values of j-potential
(over 20 mV, positive or negative) the electrostatic repulsions
between particles are strong enough to ensure their colloidal
stability. At smaller values of j-potential, particles can ﬂocculate,
except if they have sterical repulsion like in the case of PEG coating.
Anyhow, the aqueous suspensions of both LMTX and LMTX-gH625
appear as stable colloids.
3.1.4. MTX loading efﬁciency and release kinetics
The drug loading efﬁciency calculated from the unloaded MTX
absorbance at l = 655 nm was found at least as high as 97% of theFig. 2. Effect of combination of Triton and EDTA on LMTX and LMTX-gH625. Both
liposomes were treated by Triton X-100 (TX-100) and 10 mM of EDTA at 37 C. The
presence of EDTA brought full restoration of MTX absorbance intensity in LMTX-
gH625, while on LMTX had not effect.total amount incubated and it was nearly the same in both
LMTX-gH625 and LMTX.
In spite of the same concentration inside the liposomes, the
MTX ﬂuorescence intensity from LMTX in aqueous suspension was
about 5.7 times higher than in LMTX-gH625. The MTX ﬂuorescence
in gH625 should be partially quenched by Cu ions used to catalyse
the peptide coupling to the liposomes. This hypothesis was
conﬁrmed by the experiment described below. Both LMTX and
LMTX-gH625 were dissolved by treatment with 0.2% of Triton X-
100 and incubation for 1 h with EDTA (10 mM) at 37 C. This
treatment brought to a full restoration of MTX absorbance
intensity of MTX released from LMTX-gH625, while for LMTX,
which did not contain copper, the absorbance intensity of the
released drug was not affected (Fig. 2). Therefore, copper ions are
able to penetrate LMTX-gH625 and to quench there the loaded
MTX ﬂuorescence and absorbance; however, once the drug escapes
from the liposomes, the quenching is no more active.
There were no pronounced differences between LMTX and
LMTX-gH625 from the point of view of the drug release kinetics in
vitro, in HEPES–NaCl buffer (Fig. 3). Less than 30% of loaded MTX was
released within 24 h, indicating the good stability of liposomes.
3.2. Biological activity of LMTX and LMTX-gH625 in HeLa cells in vitro
The cytotoxicity of liposomes was evaluated staining Triptan
Blue on HeLa cells. Within 4 and 6 h treatment duration,
cytotoxicity was higher for LMTX-gH625 than LMTX (Fig. 4a). At
48 and 72 h we did not notice signiﬁcant differences between the
two types of liposomes; indicating that at high incubation times
both are signiﬁcantly toxic to the cells. We thus selected 1 and 4 h
for further experiments as these were more representative of the
differences between the two nanosystems.
Flow cytometry allowed us to compare quantitatively the MTX
uptake by HeLa cells treated with LMTX-gH625 or with LMTX
(Fig. 4b). We clearly observed an increased uptake of MTX from
liposomes decorated with gH625.
For better understanding of the observed cytotoxicity and
uptake details, we determined the subcellular distribution and
interaction of the delivered MTX in live HeLa cancer cells using
confocal spectral imaging (CSI) technique. As described above, theFig. 3. Kinetics of in vitro release of MTX from LMTX and LMTX-gH625.
Fig. 4. Cytotoxicity of liposomes on HeLa cells at several times of incubation (panel
a). Flow cytometry data on the MTX uptake by HeLa cells (panel b).
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each scanned point of the cell and therefore exploiting both the
spectral shape and intensity.
Full ﬂuorescence spectra (in the 640–920 nm range) were then
recorded via point-by-point scanning of the equatorial optical
section of the treated cells (see material and methods). From these
spectra, the parametric maps were generated using either total
ﬂuorescence intensity (area of the whole spectrum) or coefﬁcients
determined from ﬁtting each experimental spectrum with spectra
characteristic of 3 intracellular molecular interactions of the drug:
(i) MTX at lipophilic environment, where the spectrum is very
close in shape to that of the drug in LMTX in suspension (blue zones
and spectra in Fig. 5); (ii) MTX in nucleus, where a signiﬁcant
bathochromic shift of the spectrum is observed due to the drug
intercalation between DNA base pairs (green zones and spectra);
and (iii) an oxidative metabolite of the drug stained in the low
polarity environment, with the blue-shifted spectrum (red zones
and spectra). These characteristic spectra are consistent with those
we previously reported for the MTX incubated as aqueous solution
to MDA-MB-231 and MCF-7 cancer cell lines (Vibet et al., 2007).
In the present study, the fact that not only the blue spectra but
also the shifted ones were observed indicates that the drug was
released, at least in part, from the liposomes and was able to reach
the nucleus. Interestingly, the blue and red spectra were highly
co-localized in some perinuclear regions, indicating that the
lipophilic locations favour the drug oxidative metabolism. In ourprevious study (Vibet et al., 2007), we found the metabolite to be
co-localized with the ﬂuorescent label of endoplasmic reticulum
and its presence correlated with higher sensitivity of cancer cells to
chemotherapeutic drug MTX. From the point of view of the
ﬂuorescence intensity, it is difﬁcult to establish the exact quantum
yields (QY) in these three subcellular situations. Nevertheless, it is
commonly believed that the lower polarity environment of
ﬂuorophore favours higher QY, while the DNA intercalation leads
to a partial quenching of the drug ﬂuorescence. In this consider-
ation, the intensities used in Fig. 5 allow only a comparative
discussion, but could be calibrated to concentrations once the QY
are established (it was not a subject of the present study).
The results shown in Fig. 5 allow to analyse two effects, that of
incubation duration (1 h vs 4 h) and that of the liposomes
functionalization with gH625. The spectral maps show that the
increase of the incubation duration from 1 h to 4 h, determines a
signiﬁcant increase of the total intracellular drug ﬂuorescence (2–5
fold, see the statistical summary in Fig. 5). Similar total
ﬂuorescence intensity was reached with both types of nano-
systems. In contrast, for the LMTX and not for the LMTX-gH625, 4 h
vs 1 h incubation resulted in a subcellular redistribution of the MTX
ﬂuorescence: the relative fractions of lipophilic vs nuclear
locations were inversed. The analyses of this inversion together
with the nearly 2-fold increase of total intensity in LMTX between
1 and 4 h, leads one to the supposition that the total drug in the
nucleus is probably not decreased while the drug presence in the
perinuclear locations is more pronounced. For the LMTX-gH625,
the drug ﬂuorescence from the hydrophobic perinuclear regions
was dominant even after only 1 h of incubation and the subcellular
distribution remained nearly constant between 1 h and 4 h of
incubation. The latter means that the 5-fold increase of the
intracellular ﬂuorescence intensity for the gH625-modiﬁed lipo-
somes is related to the increased uptake of the liposomes and not
to the QY changes.
The subcellular distribution of MTX delivered with liposomes
was different from that of MTX in solution: while the drug solution
was mainly and rapidly stained in nucleus of cancers cells (Vibet
et al., 2007), liposomes mainly directed the drug to the perinuclear
zones where the metabolite production/staining by the cells was
also more signiﬁcant than with solutions. This could be the effect of
the liposomal delivery of MTX.
The above described results lead to the following conclusions
about the effect of the liposomes functionalization with gH625: (i)
it makes the MTX uptake to the hydrophobic perinuclear staining
zones even more efﬁcient; (ii) it favours even more the presence of
an oxidative metabolite of the drug in the same perinuclear
regions.
4. Discussion
Cell penetrating peptides (CPPs) have recently attracted much
interest as very efﬁcient agents to enhance drug delivery into
target cells. Amongst the CPPs, gH625 represents a novel sequence
with great possibility of overcoming the known limits of classical
CPPs. In previous studies, we have demonstrated that gH625 acts
as a potent vector for the cell delivery of molecules and
nanosystems (Galdiero et al., 2015). It is widely accepted that
drug intracellular distribution changes when they are bound to
CPPs (Tarallo et al., 2011; Aroui et al., 2009). The clariﬁcation of the
mechanism of internalization could be useful to improve
the design of anticancer delivery tools that may determine an
increase of internalization and may also help in overcoming
resistance problems. The purpose of this study was to explore the
possibility of using nanoliposomes decorated on their external
surface with a novel CPP gH625 to change and enhance the
internalization of MTX. We used CSI to distinguish very ﬁne
Fig. 5. In vitro study of subcellular interaction and distribution of MTX delivered from LMTX and LMTX-gH625 to live HeLa cancer cells. Left panel: representative images of
individual cells, i.e. merge of the white light images with the ﬂuorescence spectral maps showing either total spectral intensity (yellow zones) or merged spectral maps
characteristic of 3 intracellular molecular interactions of the drug: MTX at lipophilic environment (blue zones and spectra), MTX-DNA complex in nucleus (green zones and
spectra) and presence of an oxidative metabolite of the drug (red zones and spectra). Average spectra of the respective cells are shown in the middle column. Right panel:
statistical summary of the data over a population of at least 6 cells. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version
of this article.)
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intracellular microenvironments.
The obtained results clearly show that the presence of gH625 on
the surface of liposomes is favouring their uptake in HeLa cells: in
fact, a greater quantity of MTX is internalized (Fig. 4b). This
correlates well with toxicity data (Fig. 4a). Within 4 h, the
LMTX-gH625 was more active than LMTX. The gH625 peptide
probably induced a greater and more rapid internalization, which
could contribute to the earlier cytotoxicity of LMTX-gH625
compared to LMTX. It has also been reported in literature that a
fast cytoplasmic delivery of the drug can be related to a better
chance to overcome drug resistance (Shen et al., 2009). Neverthe-
less at high incubation times there were no signiﬁcant differences.
From the CSI spectra, we detected 3 intracellular molecular
situation for the drug: MTX at lipophilic environment, MTX in
nucleus and an oxidative metabolite of the drug stained in the low
polarity environment. The spectra observed indicate that the drug
was partially released from the liposomes and was able to reach
the nucleus; moreover, the effect of gH625 consists also in an
increased presence of an oxidative metabolite of the drug which
we previously demonstrated to be correlated with sensitivity of
cancer cells to chemotherapy by MTX (Vibet et al., 2007).
We observed that Cu is able to lead to a partial ﬂuorescence
quenching for MTX loaded in LMTX-gH625. If we assume that a
fraction of subcellular MTX found in lipophilic environment is still
encapsulated in liposomes, it means that the real amount of
internalized LMTX in presence of gH625 is even higher than what
was estimated.Our results support the view that, in addition to the nuclear one,
several mechanisms may be involved in the cytotoxicity of
LMTX-gH625 internalization.
5. Conclusions
The efﬁcient passage of drugs across the cell membrane
remains a major challenge for drug delivery. To address this need,
CPPs seem promising as they can facilitate the entry of different
covalently attached bulky cargo into cells without requiring
speciﬁc receptors. However, the mechanism of internalization of
these peptides is greatly dependant on the CPP used, the
concentration, the type of cell line, and cargo carried. The uptake
of CPPs is essentially mediated via endocytic pathways, although
the exact mechanism of cellular uptake still remains controversial,
and the endocytic uptake mechanism limits their use for drug
delivery applications. gH625 is a membranotropic peptide derived
from a viral fusion glycoprotein which is able to locally destabilize
the membrane bilayer and thus cross the cell membrane with a
mechanism which is essentially involving non-endocytic
pathways. Previous studies allowed to verify that gH625 is able
to modify the uptake mechanism of several nanosystems. Here, we
further characterized this uptake mechanism and we found that
gH625 modiﬁes the internalization of liposomes and therefore the
drug transport to the cells. Although the liposome-mediated drug
delivery to the nucleus is delayed compared to the drug solution, it
could be compensated by complementary mechanisms of
cytotoxicity taking place into the cytosol, namely those involving
66 E. Perillo et al. / International Journal of Pharmaceutics 488 (2015) 59–66the oxidative metabolism of the drug. These mechanisms are of
particular interest for the anticancer activity evaluation of the
nanosystems for drug delivery. Our studies demonstrated that the
cellular uptake of liposomes is signiﬁcantly enhanced by
the coupling of gH625 and the mechanism of uptake is modiﬁed.
In the long run, we believe that the use of gH625 combined with
the identiﬁcation of the optimal sequences for targeting various
cancers, will enable successful design of drug delivery platforms
for the development of novel theranostic systems.
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